2023 Documentation Medication Dispensing 
Proxsys Rx
APRIL 4, 2024
Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.
Proxsys Rx
AUGUST 22, 2023
Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Proxsys Rx
DECEMBER 22, 2023
Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.
FDA Law Blog: Biosimilars
OCTOBER 17, 2023
Background The Breakthrough Devices Program, established under section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), is a voluntary program for certain medical devices and device-led combination products. By Philip Won & Lisa M. Wysa, see here ) and addiction (e.g., reSET-O, see here , here ).
Proxsys Rx
JUNE 4, 2025
HHS (2023) Court: U.S. Increased Scrutiny : Regardless of court rulings, the spotlight on 340B program integrity means hospitals must tighten eligibility and documentation controls. More than ever, hospitals need to be ready at all times to document how their specialty pharmacy programs align with patient care goals and 340B intent.
Expert insights. Personalized for you.
52 
Let's personalize your content